Altimmune’s investigational obesity treatment pemvidutide preserved lean muscle mass while inducing weight loss in adults with obesity, with the majority of the drop in body weight from fat, according to a data readout of the Phase II MOMENTUM study unveiled on Sunday.
Alnylam’s Amvuttra reduced the risk of all-cause death or recurrent cardiovascular events by at least 28% in patients with transthyretin amyloidosis with cardiomyopathy, the company announced today.
Novo Nordisk’s Wegovy elicited greater weight loss in women than in men with heart failure, according to data presented Sunday at the American Diabetes Association’s 2024 Scientific Sessions.
CEO Jack Bailey said G1 will evaluate other uses for trilaciclib and will pursue partners to expand its use globally.
Japan’s Takeda Pharmaceutical gave India’s Sun Pharmaceutical and Cipla the rights to commercialize the gastrointestinal drug Vonoprazan in the country.
Sarepta Therapeutics’ gene therapy Elevidys will be available to Duchenne muscular dystrophy (DMD) patients who are at least 4 years old, regardless of whether they can walk, the FDA said Thursday.